ArticleResearch and practice in thrombosis and haemostasis2021
DOAC-Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples.
Article in Research and practice in thrombosis and haemostasis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- Usefulness and Limits of DOAC Removal Agents Based on Activated Charcoal in Thrombophilia Testing: Literature Review and Expert Proposals.Thrombosis and haemostasis · 2026Review
- Normalization of activated partial thromboplastin time and diluted Russell's viper venom time ratios can be safely omitted in the assessment of lupus anticoagulant.Research and practice in thrombosis and haemostasis · 2026Article
- Unresolved issues in the diagnosis and management of thrombotic antiphospholipid syndrome.Research and practice in thrombosis and haemostasis · 2025Article
- Simplified Method for Removing Direct Oral Anticoagulant Interference in Mechanical Coagulation Test Systems-A Proof of Concept.Journal of clinical medicine · 2024Article
- Comparing the Effect of DOAC-StopBritish journal of biomedical science · 2024Article
- Lupus Anticoagulant Detection under the Magnifying Glass.Journal of clinical medicine · 2023Review
- Novel Ex Vivo DOAC Removal Methods Reduce Interference in Lupus Anticoagulant Testing.Diagnostics (Basel, Switzerland) · 2022Article
- Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances.Journal of clinical medicine · 2022Review
- Direct Oral Anticoagulant removal by a DOAC filter: Impact on lupus anticoagulant testing - Evaluation on spiked and patient samples.Research and practice in thrombosis and haemostasis · 2022Article
- Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants.Research and practice in thrombosis and haemostasis · 2022Review
- Direct oral anticoagulant (DOAC) interference in hemostasis assays.Hematology. American Society of Hematology. Education Program · 2021Article
- DOAC-Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples.Research and practice in thrombosis and haemostasis · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of direct oral anticoagulants (DOACs) is a convenient therapeutic option for patients at risk of thrombosis. DOACs interfere with clot-based testing for the identification of lupus anticoagulant antibodies (LACs) in patients with antiphospholipid syndrome (APS), a common cause of acquired thrombotic disease.
objectivesTo evaluate a commercially available reagent DOAC-Stop for the removal of DOAC interference encountered in LAC testing. PATIENTS/
methodsWe collected a cohort of 73 test samples from patients on DOAC therapy identified at a large institutional coagulation laboratory from March to December 2019, along with samples from 40 LAC positive and negative control patients not on therapy. Samples were treated with DOAC-Stop and tested for anti-Xa activity and thrombin time for the removal of apixaban, rivaroxaban, argatroban, and dabigatran activity from patient samples. Treated and untreated samples were tested using the activated partial thromboplastin time, silica clotting time, and dilute Russell's viper venom time to evaluate the reliability and utility of DOAC-Stop.
resultsDOAC-Stop markedly reduced DOAC interference from test samples (
conclusionsDOAC-Stop is an effective adjunct for the clinical laboratory faced with DOAC interference in LAC testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.